Biogen Newsroom

Biogen Price Target Maintained With a $292.00/Share by RBC Capital

Dow Jones21:26 · Ratings

Biogen Analyst Ratings

Benzinga21:14 · Ratings

RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $292

RBC Capital analyst Brian Abrahams maintains $Biogen(BIIB.US)$ with a buy rating, and maintains the target price at $292.According to TipRanks data, the analyst has a success rate of 49.7% and a

Futu News19:33 · Ratings

RBC Capital Keeps Their Buy Rating on Biogen (BIIB)

TipRanks18:45 · Ratings

Biogen Inc. (BIIB) Cantor Fitzgerald Global Healthcare Conference (Transcript)

Earnings Call Transcripts03:36

Express News | Biogen Exec Says if FDA's Review for Subcutaneous Leqembi Is Expedited Approval Could Come After 8 Months From Submission Vs 12 Months

Breakings02:04

Express News | Biogen Exec Says Co Expects Immunogenicity Data to Be Ready by October to Submit to FDA for Subcutaneous Leqembi Filing - Cantor Fitzgerald Conference

Breakings01:58

Express News | Biogen Canada: Regulatory Decision on New Drug Submission for Omaveloxolone Is Anticipated in Early 2025

BreakingsSep 17 21:39

Biogen's New Drug Submission for Omaveloxolone Accepted for Priority Review by Health Canada for the Treatment of Friedreich's Ataxia

Yahoo FinanceSep 17 21:38

Here's Why Biogen Inc. (BIIB) Is a Strong Value Stock

Yahoo FinanceSep 16 21:40

Cautious Optimism Amidst Growth Deceleration and Rising Competition for Biogen

TipRanksSep 15 18:16

US Rheumatologists Believe Biogen's Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data

GlobeNewswireSep 13 04:36

Jones Research Starts Larimar at Buy, Cites Lead Asset Nomlabofusp

Seeking AlphaSep 13 03:58

Healthcare Stocks Have Popped. Consider These 2 That Haven't. -- Barrons.com

Barron'sSep 13 03:32

Biogen Names Lloyd Minor, Menelas Pangalos to Board >BIIB

Dow JonesSep 12 19:31

Express News | Biogen Board Appoints Two New Independent Directors

BreakingsSep 12 19:30

Press Release: Biogen Board Appoints Two New Independent Directors

Dow JonesSep 12 19:30

Bio-Thera Solutions, Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE, An Approved Biosimilar Referencing Tocilizumab In Arthritis Research & Therapy

BenzingaSep 11 20:12

Express News | Bio-Thera Solutions: Comparable Clinical Efficacy, Safety in Treatment Period 2 Is Maintained After Switch From Reference Tocilizumab to Tofidence

BreakingsSep 11 20:01

Express News | Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for Tofidence™

BreakingsSep 11 20:00